2 Years of Treatment, 7 Years of Benefits: Abemaciclib Delivers New Overall Survival Data in Breast Cancer Patients Dr. Bhumika Maikhuri26 Dec 2025 11:45 AM ISTIn this short video, Dr Nitesh Rohtagi, Principal Director, Department of Medical Oncology, Fortis Cancer Institute, Delhi and Gurugram, discusses...
Night shifts aren't just tiring, they can be deadly, suggests study Dr. Kamal Kant Kohli25 Dec 2025 8:30 PM ISTWorking the night shift, frequently flying across time zones or keeping an irregular sleep schedule does more than just leave us exhausted; it can...
Fixing disrupted body clock rhythms found to lower cancer risk: Study Anshika Mishra25 Dec 2025 8:15 AM ISTCancer doesn't just grow-it disrupts the body's natural rhythm. A groundbreaking study from Cold Spring Harbor Laboratory, led by Dr. Jeremy Borniger,...
ESMO 2025 Update: Effect of Abemaciclib added to standard Endocrine Therapy in High-Risk Early Breast Cancer Medical Dialogues Team23 Dec 2025 11:30 AM ISTAdjuvant abemaciclib combined with endocrine therapy (ET) has demonstrated a statistically significant and clinically meaningful improvement in...
AstraZeneca-Daiichi Sankyo Enhertu gets USFDA Breakthrough Therapy Designation in HER2-positive early breast cancer Ruchika Sharma22 Dec 2025 1:30 PM ISTCambridge: AstraZeneca and Daiichi Sankyo has announced that Enhertu (trastuzumab deruxtecan) has been granted Breakthrough Therapy Designation (BTD)...
SABCS: Novel endocrine therapy reduces the risk of breast cancer recurrence Dr. Kamal Kant Kohli22 Dec 2025 5:30 AM ISTIn an international study led by UCLA, researchers have shown that giredestrant, a next-generation oral selective estrogen receptor antagonist and...
Sentinel lymph node biopsy may be safely omitted in some patients with early-stage breast cancer: Study Dr. Kamal Kant Kohli18 Dec 2025 8:30 PM ISTSkipping sentinel lymph node biopsy (SLNB) in patients with clinically node-negative, hormonal receptor (HR)-positive, HER2-negative early-stage...
AstraZeneca Pharma India wins CDSCO permission to import breast cancer drug Datverzo Ruchika Sharma18 Dec 2025 3:15 PM ISTBangalore: AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organization (CDSCO),...
AstraZeneca-Daiichi Sankyo Enhertu Combo wins USFDA approval for 1st-line HER2-Positive Metastatic Breast Cancer Ruchika Sharma16 Dec 2025 12:30 PM ISTCambridge: AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) in combination with pertuzumab has been approved in the US for...
Criteria-Independent Genetic Testing Enhances Breast Cancer Risk Identification: JAMA Dr Riya Dave15 Dec 2025 8:45 PM ISTResearchers have demonstrated in the WISDOM trial that integrating criteria-independent genetic testing into routine breast cancer risk assessment is...
